Welcome to our dedicated page for Akari Therapeutics news (Ticker: AKTX), a resource for investors and traders seeking the latest updates and insights on Akari Therapeutics stock.
Akari Therapeutics plc develops oncology antibody-drug conjugates built around RNA splicing modulator payloads. News about AKTX centers on its ADC platform, the PH1 payload technology, and lead program AKTX-101, a TROP2-targeted ADC studied in solid tumor models including bladder, lung and breast cancer. Updates also cover intellectual-property protection for the company’s payload chemistry and therapeutic applications.
Recurring company developments include preclinical data releases, oncology conference abstracts, strategic development collaborations, capital-structure disclosures, governance matters, and American Depositary Share program updates. As an ADR issuer, Akari’s news may also address ordinary-share and ADS mechanics tied to Nasdaq listing requirements and shareholder approvals.
Akari Therapeutics (Nasdaq: AKTX) will present a live video webcast on Tuesday, February 10, 2026 at 1:00 PM EST as part of Webull Financial’s Corporate Connect Webinar Series.
CEO Abizer Gaslightwala will provide a corporate overview of Akari’s ADC platform, the proprietary PH1 spliceosome‑modulating payload, lead program AKTX‑101 (Trop2‑targeting ADC), IND‑enabling activities toward a first‑in‑human trial in late 2026 or early 2027, and a brief update on AKTX‑102.
Akari Therapeutics (NASDAQ: AKTX) filed U.S. provisional patent No. 63/958,508 for AKTX-102, a CEACAM5-targeted ADC that pairs a novel antibody construct with Akari’s PH1 spliceosome payload.
The filing claims composition-of-matter protection for antibody design and ADC constructs and expands Akari’s PH1 patent family. CEACAM5 expression cited: 80–90% of gastrointestinal cancers, ~30% bladder, 25% lung adenocarcinomas, up to 50% luminal A breast. Akari plans IND-enabling work for AKTX-101 with FDA interactions in H1 2026 and aims for IND/CTA submission end-2026/early-2027.
Akari Therapeutics (Nasdaq: AKTX) released a CEO Corner featuring CEO Abizer Gaslightwala summarizing 2025 progress and steps toward a clinical transition in 2026. The update highlights advancement of a novel ADC payload platform built on the proprietary PH1 spliceosome‑modulating payload, described as having a dual mechanism of direct tumor cytotoxicity plus immune activation and a compelling preclinical efficacy and safety profile. In 2025 the company announced a strategic manufacturing partnership with WuXi Biologics and began CMC and pre‑filing activities to support clinical readiness. Akari plans to initiate a First‑in‑Human trial as early as the end of 2026.
Akari Therapeutics (Nasdaq: AKTX) will present in person at the 2026 Biotech Showcase in San Francisco on Tuesday, January 13, 2026 at 9:30 AM PST in Yosemite A (Ballroom Level).
Abizer Gaslightwala, President and CEO, will overview Akari’s ADC platform, strategic priorities and key milestones for 2026. Management will also be available for in-person one-on-one meetings with registered, qualified investors during the conference running January 12–14, 2026.
Akari Therapeutics (Nasdaq: AKTX) issued its 2025 end-of-year letter outlining progress advancing antibody drug conjugates (ADCs) built on its proprietary PH1 payload, a spliceosome-modulating mechanism. Key 2025 milestones include: initiation of GMP manufacturing with WuXi XDC to support clinical supply, filing three new patents on the PH1 payload in H2 2025, preclinical activity of lead ADC AKTX-101 across pancreatic (KRAS), urothelial, gastric and AR-V7 prostate models, and differentiated safety in non-human primates. Akari plans regulatory interactions and aims to submit IND/CTA enabling a Phase 1 start in late 2026 or early 2027, subject to regulatory clearance.
Akari Therapeutics (Nasdaq: AKTX) has initiated GMP manufacturing for its lead ADC program, AKTX-101, selecting WuXi XDC as exclusive CDMO partner to perform IND-enabling work.
AKTX-101 uses Akari’s proprietary PH1 payload, described as an RNA-splicing modulator combining cytotoxic and immuno-oncology mechanisms. Akari expects this GMP material to support a Phase 1 first-in-human study planned for late 2026 or early 2027, subject to regulatory clearance.
Akari Therapeutics (NASDAQ: AKTX) released a Virtual Investor “What This Means” segment on Dec. 18, 2025 featuring President and CEO Abizer Gaslightwala.
The video covers Akari’s spliceosome-modulating payload PH1, new preclinical data for lead ADC AKTX-101 in hard-to-treat KRAS‑mutant pancreatic cancer, and the company’s plan to advance AKTX-101 into clinical testing by late 2026/early 2027. The segment is available to watch online.
Akari Therapeutics (Nasdaq: AKTX) announced a financing expected to raise approximately $5.0 million through a registered direct offering and concurrent private placement of a total of 12,607,487 ADSs (plus matching unregistered warrants).
The registered direct portion comprises 10,043,774 ADSs and Series G warrants at a combined price of $0.3883 per ADS and warrant; the private placement covers 2,563,713 pre-funded warrants and warrants at a combined price of $0.4041. Existing note holders will convert ~$2.50 million of debt into pre-funded warrants and warrants. More than $1 million of new cash comes from directors, officers and management. Proceeds will fund R&D, working capital and general corporate purposes; closing expected on or about Dec 17, 2025.
Akari Therapeutics (Nasdaq: AKTX) reported preclinical data showing its Trop2-targeting ADC AKTX-101 has single-digit nanomolar cytotoxic potency in K-Ras G12V pancreatic ductal adenocarcinoma (PDAC) cell lines and outperformed daraxonrasib in multiple PDAC cell lines.
The release notes Trop2 is highly expressed in K-Ras mutated PDAC, AKTX-101 carries a spliceosome-modulating payload PH1, and the company expects a first-in-human trial in late 2026 with preliminary safety and efficacy results in 2027.
Akari Therapeutics (NASDAQ: AKTX) published a new CEO Corner on Dec 4, 2025 with a corporate update from CEO Abizer Gaslightwala.
The company described its ADC payload platform built around a novel PH1 payload that targets the spliceosome and reported a unique preclinical efficacy and safety profile. Akari named its lead candidate AKTX-101, a Trop2-directed ADC with a proprietary linker that delivers the PH1 payload to tumors. The company is initiating IND-enabling studies and plans to advance AKTX-101 into clinical trials in 4Q 2026.